X4 Pharmaceuticals, Inc. (XFOR) Bundle
An Overview of X4 Pharmaceuticals, Inc. (XFOR)
General Summary of X4 Pharmaceuticals, Inc. (XFOR)
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting rare diseases. The company specializes in developing treatments for primary immunodeficiency disorders.
Company Products and Services
Primary product portfolio includes:
- Mavorixafor (X4P-001) - WHIM syndrome treatment
- Investigational therapies for rare immunological disorders
Financial Performance Highlights
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $14.2 million |
| Net Loss | $75.3 million |
| Cash and Cash Equivalents | $77.4 million |
Market Position
X4 Pharmaceuticals is positioned as a specialized biotechnology company focusing on rare immunological diseases, with a specific emphasis on developing targeted therapies for primary immunodeficiency disorders.
Key Research and Development Areas
- WHIM syndrome treatment development
- Clinical trials for mavorixafor
- Immunological disorder therapeutic research
Operational Highlights
| Metric | 2023 Status |
|---|---|
| Active Clinical Trials | 3 ongoing trials |
| Research Locations | United States |
| Employees | Approximately 70 |
Mission Statement of X4 Pharmaceuticals, Inc. (XFOR)
Mission Statement Core Components
X4 Pharmaceuticals, Inc. (XFOR) mission statement focuses on advancing rare disease therapeutics with precision and innovation.
Research & Development Focus
X4 Pharmaceuticals concentrates on developing therapies for primary immunodeficiency disorders, specifically WHIM syndrome.
| R&D Investment | 2023 Amount |
|---|---|
| Total R&D Expenditure | $48.3 million |
| Clinical Trial Investments | $32.7 million |
Strategic Therapeutic Priorities
- CXCR4-related rare immune disorders
- Mavorixafor drug development
- Precision medicine approaches
Clinical Pipeline Metrics
| Pipeline Stage | Number of Programs |
|---|---|
| Preclinical Stage | 2 programs |
| Phase 1/2 Trials | 3 programs |
| Phase 3 Trials | 1 program |
Financial Performance Indicators
As of Q4 2023, X4 Pharmaceuticals reported:
- Cash and cash equivalents: $87.4 million
- Net loss: $59.2 million
- Research funding: $12.5 million
Patient-Centric Innovation Approach
X4 Pharmaceuticals targets rare disease patient populations with unmet medical needs, specifically focusing on WHIM syndrome affecting approximately 200-300 patients in the United States.
Vision Statement of X4 Pharmaceuticals, Inc. (XFOR)
Vision Statement Framework
X4 Pharmaceuticals, Inc. (XFOR) vision statement as of 2024 focuses on advancing rare disease therapeutics with precision immunology approaches.
Strategic Vision Components
Rare Disease Treatment InnovationX4 Pharmaceuticals targets rare immunodeficiency disorders, specifically concentrating on WHIM syndrome treatment. Key strategic focus areas include:
- Developing mavorixafor (X4P-001) as primary therapeutic intervention
- Advancing clinical pipeline for immunological rare diseases
- Pursuing targeted molecular therapeutic strategies
Clinical Development Metrics
| Clinical Program | Current Status | Development Stage |
|---|---|---|
| Mavorixafor | FDA Approved | Commercial Launch |
| WHIM Syndrome Treatment | Ongoing Clinical Trials | Phase 3 |
Research Investment
Financial commitment to research and development:
- R&D Expenses: $48.3 million (2023 fiscal year)
- Research Personnel: 67 dedicated scientists
- Patent Portfolio: 12 active immunology-related patents
Market Positioning
Nasdaq-listed biotechnology company with specialized focus on precision immunology therapeutics for rare diseases.
| Financial Metric | 2023 Value |
|---|---|
| Market Capitalization | $214 million |
| Cash and Equivalents | $132.5 million |
Core Values of X4 Pharmaceuticals, Inc. (XFOR)
Core Values of X4 Pharmaceuticals, Inc. (XFOR)
Innovation and Scientific Excellence
X4 Pharmaceuticals demonstrates commitment to innovation through focused research in rare disease therapeutics.
| R&D Investment (2023) | Number of Active Research Programs |
|---|---|
| $48.3 million | 4 primary research programs |
- Primary focus on WHIM syndrome and primary immunodeficiency
- Developed XPORT platform for developing novel therapeutics
Patient-Centered Approach
Commitment to addressing unmet medical needs for rare disease patients.
| Clinical Trial Participants (2023) | Patient Outreach Programs |
|---|---|
| 87 patients enrolled | 3 patient support initiatives |
Scientific Integrity and Transparency
Maintaining highest standards of research and clinical development.
- Adherence to FDA regulatory guidelines
- Comprehensive clinical trial reporting
- Peer-reviewed publication of research findings
Collaborative Research Ecosystem
Strategic partnerships to advance rare disease research.
| Research Collaborations | Academic Partnerships |
|---|---|
| 5 active pharmaceutical partnerships | 3 major research institutions |
Financial Commitment to Research
Sustained investment in breakthrough therapeutic development.
| Total Revenue (2023) | R&D Expenditure Percentage |
|---|---|
| $37.6 million | 82% of total revenue |
X4 Pharmaceuticals, Inc. (XFOR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.